Methods for determining cost-benefit ratios for pharmaceuticals in Germany

European Journal of Health Economics

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Graf V D Schulenburg, J Matthias ^a   Vauth, Christoph ^a   Mittendorf, Thomas ^a   Greiner, Wolfgang ^b  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DECISION MAKING; DIAGNOSIS RELATED GROUP; ECONOMIC EVALUATION; GERMANY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH INSURANCE; HEALTH SERVICE; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; SENSITIVITY ANALYSIS; SHORT FORM 36; STANDARD;

ACADEMIES AND INSTITUTES; COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EUROPE; GERMANY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; INTERNATIONALITY; MODELS, ECONOMETRIC; NATIONAL HEALTH PROGRAMS; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 34548012137     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0063-4     Document Type: Article

References (70)

1. Akehurst, R., Anderson, P., Brazier, J.E.: Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Pharmacoeconomics 17, 443-444 (2000)
2. Akobundu, E., Ju, J., Blatt, L., Mullins, C.D.: Cost-of-illness studies: a review of current methods. Pharmacoeconomics 24, 869-890 (2006)
3. Anand, S., Hanson, K.: Disability-adjusted life years: a critical review. J. Health Econ. 16, 685-702 (1997)
4. Arnesen, T., Nord, E.: The value of DALY life: problems with ethics and validity of disability adjusted life years. Lepr. Rev. 71, 123-127 (2000)
5. Barker, C., Green, A.: Opening the debate on DALYs (disability-adjusted life years). Health Policy Plan. 11, 179-183 (1996)
6. Barton, P., Bryan, S., Robinson, S.: Modelling in the economic evaluation of health care: selecting the appropriate approach. J. Health Serv. Res. Policy 9, 110-118 (2004)
7. Brazier, J.E., Kolotkin, R.L., Crosby, R.D., Williams, G.R.: Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D. Value Health 7, 490-498 (2004)
8. Bren, L.: The importance of patient-reported outcomes.it's all about the patients. FDA Consum. 40, 26-32 (2006)
9. Briggs, A.: Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 8, 1-2 (2005)
10. Briggs, A., Sculpher, M.: An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13, 397-409 (1998)
11. Briggs, A., Sculpher, M., Dawson, J., Fitzpatrick, R., Murray, D., Malchau, H.: The use of probabilistic decision models in technology assessment: the case of total hip replacement. Appl. Health Econ. Health Policy 3, 79-89 (2004)
12. Briggs, A.H.: Statistical approaches to handling uncertainty in health economic evaluation. Eur. J. Gastroenterol. Hepatol. 16, 551-561 (2004)
13. Briggs, A.H., Gray, A.M.: Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319, 635-638 (1999)
14. Briggs, A.H., O'Brien B.J.: The death of cost-minimization analysis? Health Econ. 10, 179-184 (2001)
15. Brooks, R., Rabin, R., de Charro, F.: The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Evidence from the EuroQol BIO MED Research Programme. Kluwer Academic Publishers, Dordrecht (2003)
16. Brouwer, W.B., Koopmanschap, M.: The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics 23, 105-111 (2005)
17. Brouwer, W.B., Niessen, L.W., Postma, M.J., Rutten, F.F.: Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 331, 446-448 (2005)
18. Brouwer, W.B., Rutten, F., Koopmanschap, M.: Costing in economic evaluations. In: Drummond, M.F., McGuire, T. (eds.) Economic Evaluation In Health Care: Merging Theory And Practice. Oxford University Press, Oxford (2001)
19. Brouwer, W.B., van Exel, N.J., Baltussen, R.M., Rutten, F.F.: A dollar is a dollar is a dollar-or is it? Value Health 9, 341-347 (2006)
20. Buxton, M.J., Drummond, M.F., Van Hout, B.A., Prince, R.L., Sheldon, T.A., Szucs, T., Vray, M.: Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6, 217-227 (1997)
21. Byford, S., Torgerson, D.J., Raftery, J.: Economic note: cost of illness studies. BMJ 320, 1335 (2000)
22. Caro, J.J.: Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 23, 323-332 (2005)
23. Centre for Reviews and Dissemination.: Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. http://www.york.ac.uk/inst/crd/report4.htm (2001)
24. Claxton, K.: The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J. Health Econ. 18, 341-364 (1999)
25. Claxton, K., Sculpher, M., Drummond, M.: A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 360, 711-715 (2002)
26. Coleman, M.S., Washington, M.L., Orenstein, W.A., Gazmararian, J.A., Prill, M.M.: Interdisciplinary epidemiologic and economic research needed to support a universal childhood influenza vaccination policy. Epidemiol. Rev. 28, 41-46 (2006)
27. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., Stoddart, G.L.: Methods for the Economic Evaluation of Health Care Programms, 3rd edn. Oxford University Press, Oxford (2005)
28. EURONHEED.: Methodological Guide. http://infodoc.inserm.fr/euronheed/ edition.nsf/0/3A567E73F448E8C0C12570D40032AC53/$FILE/ Methodological_Guide_V3.pdf? openelement 3rd edn (2004)
29. Greiner, W.: Die Berechnung von Kosten und Nutzen im Gesundheitswesen. In: Schöffski, O., Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluationen. Springer, Berlin (2002)
30. Greiner, W., Schöffski, O.: Grundprinzipien einer Wirtschaftlichkeitsuntersuchung. In: Schöffski, O., Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluationen. Springer, Berlin (2002)
31. Hannoveraner Konsensus Gruppe.: Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation-Revidierte Fassung des Hanoveraner Konsens. Gesundh. Ökon. Qual. Manag. 4, A62-A65 (1999)
32. Hjelmgren, J., Berggren, F., Andersson, F.: Health economic guidelines-similarities, differences and some implications. Value Health 4, 225-250 (2001)
33. Hoffmann, C., von der Schulenburg, J.M.: Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. Eur. J. Health Econ. 1, 2-8 (2000)
34. Jacobs, P., Fassbender, K.: The measurement of indirect costs in the health economics evaluation literature. A review. Int. J. Technol. Assess. Health Care 14, 799-808 (1998)
35. Johnston, K., Buxton, M.J., Jones, D.R., Fitzpatrick, R.: Assessing the costs of healthcare technologies in clinical trials. Health Technol. Assess. 3, 1-76 (1999)
36. Jonsson, B., Weinstein, M.C.: Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. Int. J. Technol. Assess. Health Care 13, 49-58 (1997)
37. Karlsson, G., Johannesson, M.: The decision rules of cost-effectiveness analysis. Pharmacoeconomics 9, 113-120 (1996)
38. Karnon, J.: Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ. 12, 837-848 (2003)
39. Kobelt, G.: Modelle als Intrument der Gesunheitsökonomie. Gesund. Ökon. Qual. Manag. 10, 37-44 (2005)
40. Lassere, M.N., Johnson, K.R., Boers, M., Tugwell, P., Brooks, P., Simon, L., Strand, V., Conaghan, P.G., Ostergaard, M., Maksymowych, W.P., Landewe, R., Bresnihan, B., Tak, P.P., Wakefield, R., Mease, P., Bingham C.O. III, Hughes, M., Altman, D., Buyse, M., Galbraith, S., Wells, G.: Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J. Rheumatol. 34, 607-615 (2007)
41. McGuire, T., Wells, K.B., Bruce, M.L., Miranda, J., Scheffler, R., Durham, M., Ford, D.E., Lewis, L.: burden of illness. Ment. Health Serv. Res. 4, 179-185 (2002)
42. Meltzer, D.: Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. J. Health Econ. 20, 109-129 (2001)
43. Murray, C.J.: Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull. World Health Organ. 72, 429-445 (1994)
44. Murray, C.J., Acharya, A.K.: Understanding DALYs (disability-adjusted life years). J. Health Econ. 16, 703-730 (1997)
45. National Institute for Clinical Excellence.: Guide to the methods of technology appraisal. http://www.nice.org.uk/pdf/TAP_Methods.pdf (2004)
46. Nord, E.: An alternative to QALYs: the saved young life equivalent (SAVE). BMJ 305, 875-877 (1992)
47. Nord, E.: Quality adjustment of life years-possibilities, limitations, alternatives. Tidsskr. Nor Laegeforen. 112, 2668-2670 (1992)
48. Philips, Z., Bojke, L., Sculpher, M., Claxton, K., Golder, S.: Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24, 355-371 (2006)
49. Philips, Z., Ginnelly, L., Sculpher, M., Claxton, K., Golder, S., Riemsma, R., Woolacoot, N., Glanville, J.: Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol. Assess. 8, iii-xi, 1 (2004)
50. Rasanen, P., Roine, E., Sintonen, H., Semberg-Konttinen, V., Ryynanen, O.P., Roine, R.: Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int. J. Technol. Assess. Health Care 22, 235-241 (2006)
51. Ravens-Sieberer, U., Cieza, A.: Lebensqualität und Gesundheitsökonomie in der Medizin. Konzepte, Methoden, Anwendung (2000)
52. Rohrbacher, R.: Modellierungen als Grundlage für die Erstattung medizinischer Leistungen-eine internationale Perspektive. Gesund. Ökon. Qual. Manag. 10, 45-51 (2005)
53. Roviera, J.: Vorläufige Ergebnisse präsentiert auf dem Global Pricing and Reimbursement Congress 2007, Prague, Czech Republic. Pharmaceutical Pricing and Reimbursement Information (PPRI) (2007)
54. Schöffski, O., Claes, C.: Die Datenherkunft als Hauptdeterminante des Studiendesigns. In: Schöffski, O., Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluationen. Springer, Berlin (2002)
55. Schöffski, O., Greiner, W.: Das QALY-Konzept zur Verknüpfung von Lebensqualitätseffekten mit ökonomischen Daten. In: Schöffski, O., Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluationen. Springer, Berlin (2002)
56. Schöffski, O., Schulenburg, J.M.: Gesundheitsökonomische Evaluationen. Springer, Berlin (2002)
57. Schöffski, O., Uber, A.: Grundformen gesundheitsökonomischer Evaluationen. In: Schöffski, O., Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluationen. Springer, Berlin (2002)
58. Schulenburg, J.M., Greiner, W.: Gesundheitsökonomik. 2. Auflage, Mohr Siebeck, Tuebingen (2007)
59. Sculpher, M.J., Claxton, K., Drummond, M., McCabe, C.: Whither trial-based economic evaluation for health care decision making? Health Econ. 15, 677-687 (2006)
60. Siebert, U.: When should decision-analytic modeling be used in the economic evaluation of health care? Eur. J. Health Econ.4, 143-150 (2003)
61. Simoens, S.: Using the Delphi technique in economic evaluation: time to revisit the oracle? J. Clin. Pharm. Ther. 31, 519-522 (2006)
62. Stoykova, B., Drummond, M., Barbieri, M., Kleijnen, J.: The lag between effectiveness and cost-effectiveness evidence of new drugs. Implications for decision-making in health care. Eur. J. Health Econ. 4, 313-318 (2003)
63. Tarn, T., Dix Smith, M.: Pharmacoeconomic guidelines around the world. ISPOR Connections 10, 3-6 (2004)
64. Trueman, P., Drummond, M., Hutton, J.: Developing guidance for budget impact analysis. Pharmacoeconomics 19, 609-621 (2001)
65. US Department of Health and Human Services.: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual. Life Outcomes 4, 79 (2006)
66. Weinstein, M.C., O'Brien, B., Hornberger, J., Jackson, J., Johannesson, M., McCabe, C., Luce, B.R.: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-modeling studies. Value Health 6, 9-17 (2003)
67. Weir, C.J., Walley, R.J.: Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat. Med. 25, 183-203 (2006)
68. Welte, R., Feenstra, T., Jager, H., Leidl, R.: A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 22, 857-876 (2004)
69. Zentner, A., Velasco-Garrido, M., Busse, R.: Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. GMS Health Technol. Assess. Doc. 09, 1-158 (2005)
70. Zentner, A., Busse, R.: Internationale Standards der Kosten-Nutzen- Bewertung. Gesundh. Ökon. Qual. Manag. 11, 368-373 (2006)